[Adalimumab in the treatment of erythema nudosum].
Callejas Rubio
José Luis
JL
Ríos Fernández
Raquel
R
Sánchez Cano
Daniel
D
Ortego Centeno
Norberto
N
D000068879:Adalimumab; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D004893:Erythema Nodosum / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D012074:Remission Induction
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D000068879:Adalimumab